Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn
Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.
You may also be interested in...
FDA Clinical Data Standards-Setting Likely To Run Longer Than Five Years
Agency’s goal of setting standards for clinical data in 57 therapeutic areas in five years looks unlikely to be met, according to the timelines given by members of the Coalition For Accelerating Standards and Therapies.
Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, which started the project and will retain EU rights to the memantine/donepezil combo.
On Buying Spree, Colby Pharma Builds A Clinical Stage Portfolio
The privately-held Colby Pharmaceutical Company is building a portfolio of drugs through several in-licensing deals, the latest of which is with Mannkind for rights to disease-specific antigen compounds and intra-lymph node delivery technologies from a novel cancer immunotherapy program.